Institut Fuer Versorgungsforschung In Der Onkologie GbR

At Institut Fuer Versorgungsforschung In Der Onkologie GbR in Koblenz, the clinical trial portfolio focuses on cancer care across solid tumors and blood cancers. The studies are mainly designed to test new treatment options, compare them with current standard care, and improve long-term outcomes such as disease control and survival.

• Breast cancer research, including early, advanced, HER2-positive, HER2-negative, and triple-negative disease
• Lymphoma and leukemia studies, especially chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and Hodgkin lymphoma
• Lung cancer, with a focus on advanced non-small cell lung cancer
• Multiple myeloma, bladder cancer, and other advanced malignancies

The research at this site often evaluates whether new combinations or targeted therapies can improve survival, reduce recurrence, or offer better tolerability than established treatment approaches.

A large share of the studies at this oncology clinic are centered on breast cancer, covering both early-stage and metastatic disease. These trials aim to refine treatment choices for patients with HER2-positive, HER2-negative, hormone receptor-positive, and triple-negative breast cancer, with an emphasis on better disease-free survival, response rates, and overall survival.

• Early breast cancer and strategies to reduce recurrence after surgery
• Advanced or metastatic breast cancer, including treatment-resistant disease
• Testing targeted, immunotherapy-based, and antibody-drug approaches
• Comparing new regimens with standard endocrine therapy or chemotherapy

Several studies are also looking at whether treatment can be better tailored by tumor features such as HER2 status, PIK3CA mutation, and relapse risk.

This site also conducts important research in hematologic malignancies, especially chronic lymphocytic leukemia, small lymphocytic lymphoma, marginal zone lymphoma, diffuse large B-cell lymphoma, and multiple myeloma. The trials are aimed at improving disease control, reducing toxicity, and identifying better options for patients with high-risk or relapsed disease.

• Chronic lymphocytic leukemia and small lymphocytic lymphoma, including higher-risk and older or frail patients
• Lymphoma studies focused on first treatment and relapse settings
• Multiple myeloma research in relapsed and refractory disease
• Evaluating whether newer targeted therapies can improve response and progression-free survival

These studies reflect a strong interest in finding more effective and better-tolerated treatments for complex blood cancers.

Research at the Institut Fuer Versorgungsforschung In Der Onkologie GbR also includes non-small cell lung cancer and urinary bladder cancer. The main goal is to assess whether modern targeted therapies and immunotherapy combinations can improve survival and slow disease progression in advanced disease.

• Non-small cell lung cancer, especially advanced or metastatic cases
• Bladder neoplasms with spread or progression
• Testing new treatment combinations against current standards of care
• Measuring survival, response, and disease control in difficult-to-treat cancers

These trials support the broader effort to expand treatment options for patients with advanced solid tumors.